Elevated plasma tissue inhibitor of metalloproteinase‐1 level predicts decreased response and survival in metastatic breast cancer

Tissue inhibitors of metalloproteinase (TIMPs) have at least 2 different functions. They inhibit the catalytic activity of matrix metalloproteinases, and they act as growth factors.

[1]  T. Kalebic,et al.  Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation , 2006, British Journal of Cancer.

[2]  N. Pavlidis,et al.  Matrix metalloproteinases in carcinoma of unknown primary , 2005, Cancer.

[3]  N. Brünner,et al.  Tissue inhibitor of metalloproteinases-1 in breast cancer. , 2005, Endocrine-related cancer.

[4]  Henri Porte,et al.  Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent , 2005, Cancer.

[5]  N. Brünner,et al.  Tumor Tissue Levels of Tissue Inhibitor of Metalloproteinase-1 as a Prognostic Marker in Primary Breast Cancer , 2004, Clinical Cancer Research.

[6]  D. Edwards,et al.  Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). , 2002, Journal of cell science.

[7]  W. Stetler-Stevenson,et al.  Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. , 2001, The American journal of pathology.

[8]  H. Nielsen,et al.  High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  K. Brew,et al.  Tissue inhibitors of metalloproteinases: evolution, structure and function. , 2000, Biochimica et biophysica acta.

[10]  G. Li,et al.  Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. , 1999, Cancer research.

[11]  C. Luparello,et al.  Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells , 1999, Breast Cancer Research and Treatment.

[12]  A. Galloway,et al.  Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. , 1999, The Journal of surgical research.

[13]  K. O'Byrne,et al.  The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer , 1999, Thorax.

[14]  W. Stetler-Stevenson,et al.  In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. , 1998, The Journal of clinical investigation.

[15]  J. Roh,et al.  Different expression patterns of MMP-2 and MMP-9 in breast cancer. , 1998, Oncology reports.

[16]  J. Foidart,et al.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer. , 1998, British Journal of Cancer.

[17]  D. Gomez,et al.  Mammary carcinoma cells over‐expressing tissue inhibitor of metalloproteinases‐1show vascular endothelial growth factor expression , 1998 .

[18]  L. Matrisian,et al.  Changing views of the role of matrix metalloproteinases in metastasis. , 1997, Journal of the National Cancer Institute.

[19]  J. Nesland,et al.  High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Z. Werb,et al.  Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene , 1996, The Journal of cell biology.

[21]  M. Hamaguchi,et al.  Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP‐1 and TIMP‐2) , 1996, FEBS letters.

[22]  A. Buzdar,et al.  Fadrozole HCL (CGS‐16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials , 1996, Cancer.

[23]  W. Stetler-Stevenson,et al.  Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  S. Apte,et al.  The Gene Structure of Tissue Inhibitor of Metalloproteinases (TIMP)-3 and Its Inhibitory Activities Define the Distinct TIMP Gene Family (*) , 1995, The Journal of Biological Chemistry.

[25]  W. Stetler-Stevenson,et al.  The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. , 1994, The European respiratory journal.

[26]  A. Strongin,et al.  Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. , 1992, The Journal of biological chemistry.

[27]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[28]  A. Eisen,et al.  Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. , 1991, The Journal of investigative dermatology.

[29]  P. Stephens,et al.  Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity , 1985, Nature.

[30]  E. Brown,et al.  Molecular characterization and expression of the gene encoding human erythroid-potentiating activity , 1985, Nature.

[31]  D. Gomez,et al.  Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. , 1998, International journal of cancer.

[32]  K. Mimori,et al.  Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. , 1997, British Journal of Cancer.